secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEAYA Biosciences, Inc. (IDYA)
CIK:        0001676725
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0000950170-24-091175
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEAYA Q2 net loss $52.8M; darovasertib neoadjuvant UM shows tumor shrinkage; IDE397 39% ORR in MTAP-deletion tumors
--------------------------------------------------------------------------------

- Q2 net loss $52.8M vs $39.6M in Q1; R&D expenses $54.5M, up from $42.8M.
- Cash $952.7M at June 30; July public offering netted $283.8M, extending runway into at least 2028.
- Darovasertib in neoadjuvant UM: Phase 2 enrolled >50 patients; median tumor shrinkage ~72% volume; FDA Type C meeting in Q3.
- IDE397 in MTAP-deletion tumors: 39% ORR (1 CR, 6 PR), 94% DCR in 18 evaluable patients; selected 30 mg expansion dose.
- Entered option/license agreement with Biocytogen for B7H3/PTK7 BsADC; DC nomination targeted H2 2024; potential milestones $406.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1676725/000095017024091175/0000950170-24-091175-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1676725/000095017024091175/idya-20240806.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-091175

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer